article˜The œLancet. Gastroenterology & hepatologySep 23, 2016Closed access

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

Vall d'Hebron Hospital Universitari · Auckland Institute of Studies · +16 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

542
total citations
FWCI
36.25
Percentile
100%
References
52
Citations per year

Authors

22

Topics & keywords

Keywords
  • Tenofovir alafenamide
  • Tenofovir
  • Medicine
  • Double blind
  • Virology
  • Chronic hepatitis
  • Internal medicine
  • Virus
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding